title: [Long-term results of chemoradiation therapy for the patients with locally advanced (T4) esophageal cancer].
abstract: The prognosis of patients with advanced esophageal cancer is still poor. Recently, concurrent chemoradiation therapy for esophageal cancer is being utilized with increasing frequency. In this study, we reported concurrent chemoradiation for patients with T4 esophageal cancer. From July 2000, we treated 21 consecutive patients with radiation and concurrent chemotherapy using intermittent low-dose FP chemoradiation (40 Gy radiation, 2 Gy/day, for 4 weeks 280/m(2) 5-FU intermittent 24 continuous, CDDP 8 mg/m(2)/intermittent). All patients who underwent the treatment with concurrent CRT completed the planned chemoradiation. Out of 21 patients, 2 (9.5%) showed a complete response and 9 patients (42.8%) showed a partial response. The 5-year survival rate of the T4 patients with CRT was almost the same as for those who underwent surgery alone. Concurrent chemoradiation therapy for T4 esophageal cancer patients is feasible and seems to be a standard treatment for T4 esophageal cancer patients. The results indicated that CRT is an effective therapy for advanced esophageal cancer.
authors.affiliation: Dept. of Surgery II, Fukushima Medical University.
authors.forename: Koji
authors.initials: K
authors.lastname: Sekikawa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Onogi
authors.forename: Takashi
authors.initials: T
authors.lastname: Yazawa
authors.forename: Yu
authors.initials: Y
authors.lastname: Sato
authors.forename: Wataru
authors.initials: W
authors.lastname: Sakamoto
authors.forename: Kotaro
authors.initials: K
authors.lastname: Miyamoto
authors.forename: Shotaro
authors.initials: S
authors.lastname: Fujita
authors.forename: Satoshi
authors.initials: S
authors.lastname: Suzuki
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Endo
authors.forename: Shinji
authors.initials: S
authors.lastname: Ohki
authors.forename: Seiichi
authors.initials: S
authors.lastname: Takenoshita
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D002945:Cisplatin; D005472:Fluorouracil